Get the Stockscreener App
28.94
0.17%
-0.05
Spyglass Pharma Inc stock is traded at $28.94, with a volume of 75,091.
It is down -0.17% in the last 24 hours and up +20.03% over the past month.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
See More
Previous Close:
$28.99
Open:
$28.81
24h Volume:
75,091
Relative Volume:
0.68
Market Cap:
$967.98M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-5.4713
EPS:
-5.2894
Net Cash Flow:
-
1W Performance:
+9.54%
1M Performance:
+20.03%
6M Performance:
+8.47%
1Y Performance:
+0.00%
1-Day Range:
$28.03
$29.18
1-Week Range:
$25.25
$29.25
52-Week Range:
$17.06
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Name
Spyglass Pharma Inc
Sector
Industry
Phone
949-284-6904
Address
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
28.94 | 877.34M | 0 | 0 | 0 | -5.2894 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | H.C. Wainwright | Buy |
| Mar-03-26 | Initiated | Citigroup | Buy |
| Mar-03-26 | Initiated | Jefferies | Buy |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Stifel | Buy |
Spyglass Pharma Inc Stock (SGP) Latest News
SpyGlass (SGP): Finishes 1.91% Lower at $26.71; Technical Setup: the Current Price Sits Inside the Supplied Technical Range in the Available RecordWyckoff Accumulation - vinanet.vn
SpyGlass (SGP) Financial Update: Profit Per Share Falls Below Its Benchmark under the Current Snapshot - vinanet.vn
SpyGlass Pharma, Inc. (NASDAQ: SGP) Share Price, SGP Stock News, SGP Share Price & Updates - Kalkine
SpyGlass Pharma (SGP) Slides 2.4% as Shares Test Mid-Range Support ZoneBlock Trade Flow - vinanet.vn
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial - MarketBeat
Analysts Offer Insights on NA Companies: Ottobock SE & Co. KGaA (OtherOBCKF), SpyGlass Pharma (Nasdaq: SGP) and Figure Technology Solutions, Inc. Class A (FIGR) - The Globe and Mail
Raymond James Initiates SpyGlass Pharma(SGP.US) With Buy Rating, Announces Target Price $39 - Moomoo
Raymond James initiates SpyGlass Pharma stock coverage with outperform rating - Investing.com
Q3 EPS Estimates for Spyglass Pharma Decreased by Analyst - MarketBeat
SpyGlass Pharma Reports Q2 Financials, Provides Corporate Updates - VisionMonday.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
SpyGlass Pharma 2Q 2026: Net loss $(19.9)M, EPS $(0.59) — 10-Q Summary - TradingView
[10-Q] SpyGlass Pharma, Inc. Quarterly Earnings Report - Stock Titan
SpyGlass Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
SpyGlass Pharma reports $19.9M Q2 net loss, $234.2M cash and investments as of June 30, 2026 - TradingView
SpyGlass Pharma Q2 net loss widens on higher expenses - TradingView
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
SpyGlass Pharma Insiders Enjoying US$1.1m Appreciation On US$2.16m Investment - webull.com
SpyGlass Pharma (SGP) Rallies 3.08% to $24.41 as Ophthalmic Focus Draws Fresh BuyingLow Vol Factor - dars.gov.et
22,536,164 Common Stock of SpyGlass Pharma, Inc. are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com
SpyGlass Pharma (SGP) Gains 1.34% as Stock Tests Key Resistance LevelPoint of Control - dars.gov.et
SGP|SpyGlass Pharma Ord shs (Proposed)|Price:20.490|Chg%:-0.390 - TradingKey
Spyglass Pharma (NASDAQ:SGP) Shares Gap UpStill a Buy? - MarketBeat
SpyGlass Pharma, Inc. Revenue Breakdown – NASDAQ:SGP - TradingView
SpyGlass Pharma Q1 2026 Earnings: EPS Misses Estimates as Company Advances PipelineWeak Earnings Momentum - vinanet.vn
SpyGlass Pharma (SGP) Jefferies Global Healthcare Conference 2026 Summary - Quartr
SpyGlass Pharma Holds Steady Near Support as Traders Eye Key LevelsSmart Money Flow Stocks - vinanet.vn
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SpyGlass Pharma (SGP) Drops 4.77% as Key Support Levels Are TestedFade Trade - dars.gov.et
SpyGlass Pharma (SGP) Dips Nearly 5%, Testing Key Support LevelsInstitutional Flow Picks - vinanet.vn
SGP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentCore Business Growth - vinanet.vn
SpyGlass Pharma (SGP) Rallies 2.67%, Tests Key Resistance LevelRatio Spread Trade - dars.gov.et
SGP Q1 2026 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Miss Alert - dars.gov.et
SpyGlass Pharma Inc. (SGP) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Double-Digit Selloff - dars.gov.et
SGP Q1 2026 Earnings: EPS Misses Estimates, Stock Edges HigherLong-Term Guidance - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Value Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark - marketscreener.com
SpyGlass Pharma (SGP) Registration Filing Summary - Quartr
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 3000E Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Microcap Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Small Cap Completeness Index - marketscreener.com
SGP Forecast — Price Target — Prediction for 2027 - TradingView
Transcript : SpyGlass Pharma, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP) - TradingView
Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Spyglass Pharma Inc Stock (SGP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spyglass Pharma Inc Stock (SGP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):